We are live on ! Find out more
CYAD

Celyad Oncology SA American Depositary Shares
CYAD

Delisted

CYAD was delisted on the 18th of May, 2023.

Back to rankings

7 hedge funds and large institutions have $10.4M invested in Celyad Oncology SA American Depositary Shares in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more capital invested

Capital invested by funds: $8.19M → $10.4M (+$2.26M)

13% less funds holding

Funds holding: 8 → 7 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
7
Holders Change
-1
Holders Change %
-12.5%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
+$3.26M
2
Millennium Management
Millennium Management
New York
+$618K
3
Morgan Stanley
Morgan Stanley
New York
+$122K
4
Wells Fargo
Wells Fargo
California
+$10K
5
UBS Group
UBS Group
Switzerland
+$4.92K

Top Sellers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
-$33K
Name Holding Trade Value Shares
Change 		Change in
Stake
Victory Capital Management
1
Victory Capital Management
Texas
$9.62M +$3.26M +263,480 +38%
Millennium Management
2
Millennium Management
New York
$504K +$618K +50,000 New
Morgan Stanley
3
Morgan Stanley
New York
$226K +$122K +9,891 +79%
Wells Fargo
4
Wells Fargo
California
$87K +$10K +810 +10%
UBS Group
5
UBS Group
Switzerland
$9K +$4.92K +398 +80%
Bank of Montreal
6
Bank of Montreal
Ontario, Canada
$1K – – –
Zurich Cantonal Bank
7
Zurich Cantonal Bank
Switzerland
$1K – – –
Deutsche Bank
8
Deutsche Bank
Germany
– -$33K -2,900 Closed

CYAD Hedge Fund Activity: Q3 2019 in Review

7 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q3 2019, worth a combined $10.4M — up 28% from $8.19M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of CYAD and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 4 added.

The largest buyer was Victory Capital Management, adding an estimated $3.26M. The largest seller was Deutsche Bank, exiting entirely with an estimated $33K sold.

  • 7 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q3 2019, down from 8 in Q2 2019.
  • Funds reported $10.4M of Celyad Oncology SA American Depositary Shares stock for Q3 2019, up 28% quarter-over-quarter.
  • 1 fund opened new Celyad Oncology SA American Depositary Shares positions in Q3 2019 and 2 closed out, a net change of -1 holder.
  • The largest Celyad Oncology SA American Depositary Shares buyer in Q3 2019 was Victory Capital Management, an estimated $3.26M added.
  • The largest Celyad Oncology SA American Depositary Shares seller in Q3 2019 was Deutsche Bank, an estimated $33K sold.

Based on aggregated 13F filings for Q3 2019.